美國

證券和交易所委員會

華盛頓特區20549

表格 8-K

現時報告
根據第13或15(d)條款
《1934年證券交易法》

2024年8月29日

報告日期（最早報告事件日期）

agba group holding limited

（在其章程中指定的註冊名稱）

註冊人的電話號碼，包括區號：＋852 3601 8000

無數據

（如果自上次報告以來地址或名稱有變更，請填寫上次地址或名稱）

如此收件人希望，檢查以下適用的選框，指的是提交8-K表格的同時滿足註冊人根據以下任一規定的提交及報告責任:

根據法案第12(b)條註冊的證券：

請勾選相應的選項，説明報告的申報者是否符合《1933年證券法規則405條》（17 CFR §230.405）或《1934年證券交易法規則120億.2》（17 CFR §2401.2億.2）中定義的新興成長性公司的要求。

新興成長公司 ☒

如果是新興增長公司，請勾選以下項目：是否選擇不使用根據證券交易法第13(a)條提供的任何新或修訂的財務會計準則符合延長的過渡期。☐

項5.02. 董事離任或特定高管離職；董事選舉；特定高管任命；特定高管薪酬安排。

（b）合併、合併或其他業務組合（稱為“業務組合”）的結束，除了一種業務組合以後業務組合之前股東擁有普通股或普通股的相同比例所有權的業務組合之外。

(c) 將除非關聯公司以外的所有或幾乎全部公司資產出售或處置給任何實體的協議的結束；

(d) 股東批准的公司完全清算計劃，不包括公司合併為任何子公司或清算後，原公司股東在清算前後持有的普通股或普通股的比例基本相同；

（e）在任何連續二十四（24）個月中，現任董事不能構成董事會或任何繼任公司董事會的多數; 但是，獲得多數現任董事選舉入董事會或獲得現任董事通過提名的董事，應被視為本段（e）的現任董事。但出於此目的，不包括因存在候選董事選舉或其他實際或威脅性的代理人或同意函指示由董事會以外的個人、實體或“集團”（含但不限於基於本定義的段（a）、（b）、（c）或（d）進行的行為）而被選任所致的個人。

1.董事選舉

2.8“代碼”指1986年修訂後的《國內税收法典》（Internal Revenue Code of 1986），以及後續的任何修改。計劃中對代碼的任何部分的引用應視為包括該部分下的任何法規或其他解釋指導以及對該部分、法規或指導的修改或後續規定。

2.38 “限制”指根據受限股獎勵計劃（Plan）根據受限股獎勵協議（Restricted Stock Agreement）授予員工、董事或顧問的股份所適用的沒收、轉讓和/或其他限制。

2.39 “規則160億.3”指美國證券交易委員會根據《交易所法》制定的規則160億.3，該規則可能會不時修訂，並能夠完成相同或實質相似的功能的任何繼任規則、法規或法規。

項目9.01：財務報表和展覽。

(d) 展示材料。

簽名

根據1934年證券交易法的要求，申報人已授權下面簽署此報告。

Loss after tax for FY2024 was US$8800萬, a 7% increase compared to US$8190萬 for FY2023. The net loss attributable to ordinary shareholders was 8.91 US cents per share for FY2024, compared with 10.53 US cents per share for FY2023. Conference Call There will be a webcast today, beginning at 8.30am AESt (Thursday, August 29); 6.30pm EDt (Wednesday, August 28). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late- stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. Jagasia m et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749 2. Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43. 3. Wittenberg RE, Gauvreau k, Leighton J, Moleon-Shea m, Borow Km, Marx GR, Emani Sm, Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome, JTCVS Open Volume 16, Dec 2023, doi: https://doi.org/10.1016/j.xjon.2023.09.031 4. Symons JD, Deeter L, Deeter N, et al. Effect of continuous-flow left ventricular assist device support on coronary artery endothelial function in ischemic and nonischemic cardiomyopathy. Cir Heart Fail 2019; 12:e006085. DOI: 10.1161/CIRCHEARTFAILURE.119.006085. 5. Using Reserve Bank of Australia (RBA) published exchange rate from June 30, 2024 of 1A$:0.6624US$. 6. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. 7. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:140.01 Yen for the twelve months ended June 30, 2023 to 1USD:151.75 Yen for the twelve months ended June 30, 2024. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our

3